EU regulator backs approval of COVID-19 drugs from Regeneron-Roche, Celltrion
Nov 11 (Reuters) - Europe's drug regulator on Thursday
recommended https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
approving two COVID-19 therapies based on monoclonal
antibodies, one developed by U.S. biotech firm Regeneron
REGN.O and Swiss giant Roche ROG.S and another from South
Korea's Celltrion 091990.KQ .
The news comes after Reuters reported this week the approval
was imminent amid a spike in coronavirus infections.
urn:newsml:reuters.com:*:nL1N2S00ZV
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun
Koyyur)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793 ;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap